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Abstract
Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation.
PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell
(CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad anticancer activity.
Method: we investigated the effects of DZNeP on cell proliferation, tumorigenicity and invasive potential of PC cell
lines (LNCaP and DU145).
Results: Exploring GEO and Oncomine databases, we found that specific PRC2 genes (EED, EZH2, SUZ12) predict
poor prognosis in PC. Non-toxic DZNeP concentrations completely eradicated LNCaP and DU145 prostatosphere
formation, and significantly reduced the expression of CSC markers. At comparable doses, other epigenetic drugs
were not able to eradicate CSCs. DZNeP was also able to reduce PC cell invasion. Cells pre-treated with DZNeP
were significantly less tumorigenic (LNCaP) and formed smaller tumors (DU145) in immunocompromised mice.
Conclusion: DZNeP is effective both in vitro and in vivo against PC cells. DZNeP antitumor activity is in part
mediated by inhibition of CSC tumorigenic potential.
Introduction
Prostate cancer (PC) is the second leading cause of can-
cer death in men in the US [1]. Disease confined to the
prostate is curable, while metastatic PC is associated
with poor prognosis. Although endocrine therapy and
docetaxel improve patient survival, metastatic disease
eventually leads to death [2]. Thus, the identification of
new drugs to target PC progression and metastasis is
highly warranted.
In the past few years, it has been determined that PC
contains a cancer stem cell (CSC)-compartment [3]. This
compartment shares with normal stem cells an unlimited
potential for self-renewal and the ability to differentiate
in many cell types. When injected into immunocompro-
mised mice, CSCs are highly tumorigenic cells compared
to the bulk population [4] and can be as rare as 0.1% of
the total tumor mass. CSCs are considered the seeds of
tumor progression, metastasis and recurrence [5]. In
addition, they are resistant to conventional therapy.
Thus, the identification of targets that specifically inhibit
CSC growth may improve PC patient survival [6]. Tradi-
tionally, CSC have been identified by two methods: in
vitro culture of spheres in serum-replacement medium
[7], and isolation of tumorigenic cells based on the
expression of specific cell surface markers [4]. Our group
identified CD44
+/24
- cells as the tumor-initiating fraction
in LNCaP and DU145 cell lines [4]. Duhagon et al. [8],
and Dubrovska et al. [7] demonstrate that cells cultured
in serum-replacement medium supplied with specific
growth factors are highly tumorigenic and express several
CSC markers. An additional method to test “stemness”
features in cancer cells is the ability to become locally
invasive through a structural change termed epithelial-
to-mesenchymal transition (EMT) [9]. EMT is also a
model used to investigate the metastatic potential of can-
cer cells [10]. Interestingly, CSCs in PC share all these
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+/24
- cells are highly tumori-
genic, give rise to anchorage-independent growth in
serum-replacement medium[4] and are more invasive
[11].
CSCs are characterized by the expression of several
stem cell-specific genes, including nanog, oct3-4 and c-
myc [6]. Among these, Polycomb Repressive Complexes
(PRCs) play a crucial role. Polycomb genes are orga-
nized in multimeric complexes that mediate specific his-
tone post-translational modifications and gene silencing
[12]. During development, PRCs orchestrate body seg-
mentation and tissue specification. PRC2 mediates his-
tone H3 lysine 27 trimethylation, thereby silencing
lineage-specific genes and maintaining stem cell pluripo-
tency. In PC cells, PRC2 genes are over-expressed in the
CD44
+/24
- fraction[4], and are required for anchorage
independent growth[13]. In addition, Polycomb genes
orchestrate metastasis-suppressor gene silencing during
EMT [14,15]and PC chemo-resistance[16]. In particular,
The PRC2 component EZH2 is predictive of shorter dis-
ease progression and poor treatment outcome in PC
patients [17]. Thus, PRC2 could be a viable target to
deplete CSCs, counter metastatic spreading and improve
patient survival.
3-Dezaneplanocin-A (DZNeP) is an S-adenosyl-L-
homocysteine hydrolase inhibitor first tested against
Ebola virus [18]. More recently, this compound showed
a broad anticancer activity, with little or no effects on
non-transformed cells [19]. DZNeP inhibits EZH2 his-
tone methyltransferase activity, and induces protein
degradation of PRC2 components (EZH2, EED, SUZ12).
DZNeP-dependent histone demethylation reactivates a
set of PRC2-silenced genes in cancer cells, thereby caus-
ing apoptosis. Recently, DZNeP was shown to be effec-
tive against brain cancer stem cells, and to inhibit in
vivo glioblastoma formation [20].
Due to the widespread role of PRC2 genes in PC
tumorigenicity progression and invasion, we sought to
determine whether DZNeP is active against PC CSCs.
To test this hypothesis, we treated two PC cell lines
with DZNeP, specifically investigating the effects on
CSC markers, prostatosphere formation and EMT. We
also carried out in vivo experiments to test the hypoth-
esis that DZNeP impairs CSC tumorigenic potential. In
addition, we queried patient databases to investigate the
role of PRC2 genes and PRC2 targets in PC prognosis,
as well as to dissect viable pathways modulated by
DZNeP in PC cells.
Materials and methods
Cell culture
The PC cell lines LNCaP and DU145 were obtained
from American Type Culture Collection (Manassas,
VA). LNCaP cells are derived from a lymph node
metastasis and DU145 cells from a brain metastasis.
Both cell lines are derived from androgen-independent
prostate cancers. LNCaP still express the androgen
receptor (AR) and a wild-type p53 gene, DU145 are
androgen receptor negative and p53-mutated. LNCaP
and DU145 were maintained in culture medium (RPMI-
1640 and DMEM, respectively) with 10% fetal bovine
serum, glutamine (1%), and penicillin-streptomycin (1%).
DZNeP was dissolved in water and diluted in culture
medium immediately before use. Trichostatin A (TSA)
and 5-aza-2-deoxycitidine were dissolved in dimethyl
sulfoxide (DMSO) and diluted in culture medium imme-
diately before use. Final DMSO concentration never
exceeded 0.1%. The same concentration of DMSO was
used as a control for these experiments.
Cell cycle and apoptosis analysis
Cells were seeded at 50% confluence to ensure loga-
rithmic growth and treated with 1 μMD Z N e Pf o r3
and 5 days. This concentration is not harmful for non-
transformed cells[19], although it showed anti-tumor
activity. Following treatment, one million cells were
fixed in ice cold 70% ethanol overnight. Following fixa-
tion, cells were centrifuged and resuspended in PBS
containing 40 μg/mL propidium iodide and 100 μg/mL
RNAse A and incubated at 37°C for 1 hour. We did
not observe cell cycle distribution differences for a 3
day treatment. Thus, only the effects after 5 day treat-
ment will be discussed. Apoptosis assays were per-
formed as previously described [21]. Apoptosis was
also measured after treatment with 5-aza (0.5 μM, 3d)
and TSA (20ng/ml, 3d). These concentrations were
chosen because they are not harmful for normal cells
[22,23], thus they are comparable to the DZNeP dose
we employed.
Prostatosphere formation assay
Prostatospheres were generated according to the proto-
col described by Duhagon et al. [8]. Spheres number
and volume were evaluated through GelCountTM auto-
matic plate scanner (Oxford Optronics) and GelCount
Version 0.025.1 software (Oxford Optronics).
Western Blot
Total protein was isolated from LNCaP and DU145 cells
using RIPA lysis buffer (Thermo Scientific, Waltham,
MA USA) and quantified using the BCA protein assay
kit (Pierce) kit. Thirty μg of protein extract was loaded
per lane into a 4% to 20% Tris-glycine gel (Invitrogen,
Carlsbad, CA). Proteins were transferred to a polyvinyli-
dene fluoride membrane, blocked in 10% nonfat dry
milk, 0.1% Tween-20 PBS, incubated with primary (anti-
EZH2, Millipore) and secondary (LI-COR Biosciences,
Lincoln Nebraska USA) antibodies, and scanned by the
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described [4].
Cytofluorimetric Assay
Flow-cytometric discrimination, based on CD44
and CD24 expression, was performed as previously
described [4].
Matrigel invasion assay
Matrigel assays measure the ability of cancer cells to
invade through a protein matrix. This is considered an
in vitro model for early metastatic stages, namely basal
membrane invasion. We performed this assay as pre-
viously described [24]. For experiments involving isola-
tion of top ‘non-invading’ and bottom ‘invading’ cells,
parallel invasion chambers were setup. For non-invading
cells, the bottom of the membrane was scrubbed with a
cotton swab and cells on top were harvested using 500
μl of trypsin incubated at 37°C for 5 minutes. To obtain
the invading cells, the top of the membrane was
scrubbed with a cotton swab and the chambers were
placed into another 24-well plate containing 500 μLo f
trypsin incubated at 37°C for 5 minutes. RNA was
extracted from invading and non-invading cells using
the Trizol reagent. cDNA was prepared and measured
by quantitative PCR, as described[11]. An EZH2 Taq-
Man gene expression assay (Applied Biosystems) was
employed for this purpose. This experiment was not
repeated, due to the very low yield of RNA extraction
for invading cells.
Gene expression assay
DU145 cells were treated with DZNeP 10 μM, 3d. At
the end of the treatment, RNA was extracted and retro-
transcribed, as described in the previous paragraph.
Gene expression level was determined for the following
genes, involved in EMT, through validated Applied Bio-
systems assays: CDH1, FGF2, MMP3, c-MYC, SNAIL,
TGFB1, TWIST, FGF9, NRG1, TGBR2, SPOCK3. 18S
RNA was employed as a reference, and relative expres-
sion was quantified by 2
-ΔΔCtmethod. We reported only
changes greater than 2-fold.
In vivo experiments
Animal Care was provided in accordance with the pro-
cedures outlined in the ‘Guide for Care and Use of
Laboratory Animals’ (Institute of Laboratory Animal
Resources, 1996). LNCaP and DU145 cells were treated
with 1 or 10 μM DZNeP for three days. After three
days, cells were trypsinized, washed once with PBS, then
resuspended in serum-replacement medium at 1000
viable cells per 50 μl, mixed with an equal volume of
matrigel (BD Biosciences) and injected subcutaneous
into male NOD/SCID (non obese diabetic, severe
combined immunodeficiency) mice (Jackson Labs, Bar
Harbor, ME, USA). For controls, 10
6 (DU145) and 5*10
6
(LNCaP) viable cells per animal were injected (8 animals
per treatment group). Cell viability was assessed upon
trypsination through Trypan Blue staining. Untreated
cells were plated at the same time and injected into 6
NOD/SCID mice following the same procedure. Mice
were monitored daily for palpable tumour formation for
a total of 45 days. Tumour size was measured with cali-
pers. Tumour volume was determined by the following
formula: V = W
2XL/2 [25]. Once tumours reached
greater than 1.5 mm in one dimension, mice were
euthanized and tumours were collected.
Meta-analysis on patient databases
Oncomine and Gene expression Omnibus (GEO) data-
bases were queried to identify the prognostic role of
PRC2 components in PC. GEO database is available at
http://www.pubmed.org (GEO profiles) and provides
raw expression data from several gene expression arrays.
Selected data compare PRC2 gene expression in normal
prostate, primary tumor and metastasis. Data have been
selected from Varambally et al. [26] because this study
was an integrated molecular profiling of gene expression
in PC samples. In this work, a significant concordance
between EZH2 mRNA and protein was found. Onco-
mine database has been described in the previous sec-
tion. In this case, it has been employed to investigate
the correlation between PRC2 genes and PC prognosis.
In addition, Oncomine provides curated sets of genes
("concepts”). Among these, “Polycomb group (PcG) tar-
get genes in embryonic stem cells” is a set of genes spe-
cifically silenced by PcG to maintain stem cell self-
renewal. This concept was crossed with all Oncomine
concepts derived from PC clinical analysis, in order to
identify significant overlap; p-value was set at 0.01.
Statistical Analysis
Unless otherwise specified, all experiments were done in
triplicate and were repeated at least twice. Data were
expressed as mean values SE or SD and were analyzed
though GraphPad Prism software. The level of signifi-
cance was set at p < 0.05.
Results
Pc Progression is Associated with Prc2 Gene
Overexpression
To investigate the role of PRC2 gene silencing in PC
progression, we queried the Oncomine database. One
pre-defined Oncomine concept is “PcG target genes in
human embryonic stem cells”. This set includes 652
genes that were shown to be silenced by PRC2 through
H3K27 methylation in embryonic stem cells [27]. Inter-
estingly, we found that PRC2 target genes were
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stage PC. In addition, PRC2 target gene silencing pre-
dicted shorter overall survival and disease-free survival
(Table 1).
To confirm our findings, we queried the GEO data-
base to compare PRC2 gene expression in normal pros-
tate, primary tumors and metastatic samples. We found
an increase of all PRC2 components with PC progres-
sion (Figure 1A). In particular, EZH2 and SUZ12
expression was significantly higher in metastatic PC,
compared to primary tumors.
F i n a l l y ,t oc o n f i r mt h en e g a t i v ep r o g n o s t i cr o l eo f
PRC2 genes in PC, we queried PRC2 gene expression in
the Oncomine database. As shown in Figure 1B and 1C,
high EZH2 and high SUZ12 expression are positively
correlated with metastatic spreading. These results con-
firm that PC progression is associated with increased
PRC2 gene expression and PcG target gene silencing.
Dznep Activity on Pc Cells and Prostatospheres
Due to the role of PRC2 genes in PC progression and
prognosis, we tested the effect of the PRC2 inhibitor
DZNeP on LNCaP and DU145 cells. We first confirmed
that doses as low as 1 μM DZNeP were able to almost
abolish EZH2 expression (Figure 2A) and reduced his-
tone H3K27 trimethylation by 33% (quantification per-
formed by LI-COR Odyssey IR Imaging System;
Additional File 1). This is in line with the evidence that
histone lysine methylation can be mediated by enzymes
other than EZH2[28]. In LNCaP cells, EZH2 silencing
was already evident after 3 days, while in DU145 cells
we could find an effect after 5 days. Annexin-PI staining
showed that DZNeP was able to trigger early and late
apoptosis in DU145 cells (Figure 2B). We did not
observe this effect on LNCaP cells. Cell cycle analysis
showed that DZNeP treatment did not affect cell cycle
distribution in DU145 cells, while inducing a consistent
G0/G1 arrest in LNCaP cells (Figures 2C,D). For our
experiments, we used DZNeP doses that showed anti-
cancer activity, but were not harmful for non-trans-
formed cells. In order to compare DZNeP activity with
other commonly used epigenetic drugs, we treated
LNCaP and DU145 cells with Trichostatin A (TSA) and
5-aza-2-deoxycitidine (5-aza) at doses non-toxic for nor-
mal cells[22,23]. As shown in Additional File 2, both
drugs did not induce significant apoptosis in cancer
cells.
Due to its effect on total cancer cells, we tested the
hypothesis that 1 μM DZNeP was effective in inhibiting
prostatosphere (PS) formation. We used a 1 week treat-
ment in SCM, because PS form PC cell lines formed
after 1 week culture in stem cell medium are enriched
for CSCs and highly tumorigenic [8]. As shown in
Figure 3, PS formation was completely abrogated by 1
μM DZNeP in both LNCaP and DU145 cells. Cells trea-
ted with DZNeP were generally unable to grow as
spheres, and assumed a branched shape (Figure 3A). In
both cell lines, sphere growth inhibition was higher than
95%. Mean sphere diameter was reduced more than 2-
fold in DU145 cells, and almost undetectable in LNCaP
cells. Interestingly, non-toxic doses of TSA and 5-aza
were not able to eliminate PS formation (Additional
File 3). In particular, 5-aza reduced sphere number by
50% in LNCaP cells, with weaker effect on DU145 cells.
TSA eradicated PS formation in LNCaP cells (more
than 95% inhibiton) but not in DU145 cells. Both drugs
had weaker effects in comparison to DZNeP on PS dia-
meter. These results show that DNZeP is effective in
inhibiting PC cell growth in vitro, is selective for PC
cells at doses higher than 1 μM, and abrogates PS self-
renewal.
To further corroborate our findings, we investigated
the effects of DZNeP treatment on CSC markers (CD44
and CD24). After DZNeP treatment (1 μM, 3d), LNCaP
cells showed a decrease in the CD44
+/24
- fraction,
which is the CSC-enriched population (figure 3D). Inter-
estingly, DZNeP treatment also increased the CD44
-/24
+
fraction, which is represented by more differentiated
cancer cells. Keeping with this observation, CD44
+/24
-
sorted cells were almost completely killed by the same
DZNeP schedule (1 μM, 3d) (Additional File 4).
Effects of Dznep on Pc Invasion and Tumorigenicity
Since PRC2 genes seem to be involved in PC progres-
sion and metastatic spreading (Figure 1), we tested the
hypothesis that DZNeP is able to inhibit in vitro
Table 1 Prognostic role of PcG-target genes in PC samples
ASSOCIATED CONCEPT P VALUE ODDS RATIO
Dead at 3 Years Top 10% Under-expressed (Nakagawa Prostate 2) 5.65E-04 6.1
Recurrence at 5 Years - Top 5% Under-expressed (Holzbeierlein Prostate) 0.001 2.5
High Grade Top 1% Under-expressed (Bittner Prostate) 0.001 2.6
Advanced N Stage Top 10% Under-expressed (Nakagawa Prostate 2) 5.65E-04 6.1
Advanced Stage Top 5% Under-expressed (Dhanasekaran Prostate) 0.04 2.2
The Oncomine concept “PcG target genes in human embryonic stem cells” was crossed with all available prognostic data in PC samples (associated concepts).
PcG target genes are significantly underexpressed in poor-prognosis, high stage PC. In brackets, Oncomine identification name.
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Figure 2 Effects of DZNeP on PC cells.A ,W e s t e r nb l o ta n a l y s i s .( - ) ,u n t r e a t e dc e l l s .B ,A nnexin-PI staining on untreated and treated cells.
Columns mean volume. C, D: cell cycle distribution after DZNeP treattment. Columns, mean volume. Cells were treated with 1 μM DZNeP for 3
and 5 days.
EZH2 (ONCOMINE) SUZ12 (ONCOMINE)
1 2 2 1 2
*
**
P=1.44 E-4 P=0.002
A
B C
Figure 1 PRC2 gene expression in PC patients. A, comparison of PRC2 mRNA levels in normal prostate, primary and metastatic PC (GEO
database). *p < 0.05, **P < 0.01. B, C: prognostic role of EZH2 and SUZ12 mRNA levels in PC sample (Oncomine database).
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cells with DZNeP, we then measured the concentration
of viable cells through Trypan Blue staining, and then
plated the same number of treated and untreated cells
in a Matrigel invasion assay. This procedure discrimi-
nates between a general antitumor effect and a specific
inhibition of invasion (Figure 4A). DU145 cells were
generally more invasive than LNCaP cells. DZNeP sig-
nificantly inhibited invasion in DU145 cells, but had no
effect on LNCaP cells. To investigate the role of PRC2
genes in this process of invasion, we then compared
EZH2 mRNA expression in invasive vs. non-invasive
cells. EZH2 was markedly up-regulated after invasion
(Figure 4B), however, EZH2 up-regulation was almost
20-fold higher in DU145 than in LNCaP cells. These
results show that PRC2 genes are crucial for invasion in
DU145, but not in LNCaP cells. To further investigate
mechanisms of EMT inhibiton by DZNeP, we measured
gene expression changes in 11 EMT-related genes. As
shown in Additional File 5, DU145 cells treated with
DZNeP showed more than 2-fold down-regulation of
TGBR2 (TGF-b receptor 2) and SNAIL.
Finally, we tested the hypothesis that DZNeP treat-
ment was able to impair tumorigenicty and tumor
growth. For this purpose, we treated LNCaP and DU145
cells with 1 and 10 μM DZNeP (3 d) and then injected
cells into immunocompromised NOD/SCID mice. For
each cell line, the same number of viable treated and
untreated cells was injected. We then measured time to
palpable tumor formation and tumor volume for 45
days after injection. In LNCaP cells, 10 μM DZNeP was
able to significantly inhibit time to tumor formation
(Figure 4C), while in DU145 cells we did not observe
this effect. However, DZNeP-treated cells formed
tumors with a significantly slower growth rate, com-
pared to untreated cells. For the 1 μMd o s e ,w e
observed a significant difference in tumor volume for as
long as 30 days after injection. For the 10 μM dose, this
difference was still significant after 45 days (Figure 4D).
Discussion
In the present work, we investigated the effects of the
PRC2 inhibitor DZNeP on prostate CSCs, invasion and
in vivo tumor growth. Our clinical data meta-analysis
indicated that PRC2 genes are specifically silenced dur-
ing PC progression, and that high expression of PRC2
genes is a negative prognostic factor in PC. These
results confirm and broaden the already established
role of EZH2 in PC progression[29]. In particular, we
found that another member of PRC2 (SUZ12) is highly
predictive of metastatic spreading, and that PRC2 tar-
get gene silencing is involved in PC progression, and
LNCaP
Untreated                     1μMDZNeP
Untreated           1uM DZNeP
Serum-replacement medium A
C
B
LNCaP DU145
D
LNCaP DU145
Figure 3 Effects of DZNeP on PS and CSC markers. A, representative picture of cells grown in SCM for 7 days. B, C PS number and volume in
untreated and treated cells (1 μM, 7 days). Columns, mean volume; bars standard deviation. D, CSC marker expression. LNCaP cells were treated
with DZNeP (1 μM, 3 days) and then sorted as described under “Flow cytometric analysis and separation”.
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genes are crucial for CSC self-renewal, and are thought
to sustain PC growth [12] Thus, we tested the hypoth-
esis that PRC2 inhibition affects PC tumorigenicity.
We found several lines of evidence supporting this
hypothesis. For our experiments, we employed 1 and
10 μM, 3d/5d-schedule, to make our results compar-
able to previously published data [19,20,30]. Doses as
low as 1 μM DZNeP were able to inhibit PRC2-
mediated H3K27 methylation, and displayed antitumor
activity against PC cells (Figure 2). Interestingly, this
schedule was shown to be non-toxic for normal cells
[19]. In order to compare DZNeP to other epigenetic
drugs, we tested PS formation in the presence of
DNA-methyltransferase inhibitor 5-aza, and histone
deacethylase inhibitor (HDACi) TSA. Non toxic con-
centrations of 5-aza did not affect PS formation. To
the contrary, TSA eradicated PS in LNCaP, but not in
DU145 cells (Additional File 3). These results suggest
that DZNeP is more effective than other epigenetic
drugs in eradicating PS. Interestingly, TSA seems to be
more effective than 5-aza. Since HDACi were shown
to indirectly target PRC2[31], we think that TSA
effects on PS is in part mediated by PRC2 inhibition.
Keeping with this hypothesis, it has been recently
shown that 5-aza does not reactivate PRC2 targets in
cancer cells[32].
In LNCaP cells, DZNeP treatment caused G0/G1 phase
arrest, but was not able to trigger apoptosis. To the con-
trary, PRC2 targeting induced apoptosis in DU145 cells.
This is interesting, since most antitumor treatments are
generally more effective on LNCaP cells, which are
thought to be a model for less aggressive and more che-
mosensitive PC [33]. Indeed, LNCaP cells express AR and
a wild-type p53 protein, which are markers of early PC. In
addition, DU145 cells are almost 100% CD44
+, while the
CSC fraction in LNCaP cells is less than 0.1% [4]. Accord-
ing to this proteomic profile, DU145 cells are more
tumorigenic and more invasive than LNCaP cells [4,11].
Our results show that DZNeP specifically kills the CSC
fraction in LNCaP cells (Figure 3D), while inducing apop-
tosis in all DU145 cells (Figure 2B), which are more
“stem-like” cells. Interestingly, non-toxic concentration of
other epigenetic drugs (TSA and 5-aza) were not able to
**
*
DU145 LNCaP
**
**
Non-Invasive Invasive
A
C
B
D
*
Figure 4 Effects of DZNeP on invasion and in vivo tumor growth. A, Cells were treated with DZNeP (1 μM, 3 days) and assayed for cell
viability at the end of the treatment (trypan blue staining). Alive cells were used for Matrigel invasion assay, as described in “Materials and
Methods”. Columns, mean volume; bars, standard deviation. **p < 0.01 with respect to untreated cells (T test). B, mRNA levels in invading and
non-invading cells (QT-PCR). C, effects of DZNeP on LNCaP cell tumorigenicity. **p < 0.01 (log rank test) with respect to untreated cells. D,
effects of DZNeP on DU145 xenograft tumor volume. *p < 0.05 with respect to untreated cells (U test). Star colors refer to dose treatment (blue,
1 μM; red, 10 μM). Number of animals: untreated: 6; 1 and 10 μM: 8. Point, mean value; bar, standard deviation.
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may be peculiar among epigenetic modifers
We also found that DZNeP significantly inhibits inva-
sion in DU145, but not in LNCaP cells (Figures 4A,B).
A recent work showed that EZH2 gene silencing has dif-
ferent effects on PC cell lines [11]. In particular, EZH2
knockdown was less efficient in DU145 cells than other
cell lines. Despite this, EZH2 silencing significantly
reduced growth rate and invasion in these cells. To the
contrary, EZH2 silencing on LNCaP cells had an effect
on growth rate but not on invasiveness. The authors
suggested that DU145 cells are particularly dependent
on PRC2 function, like other AR-negative cells, and that
the dependence on AR signaling decreases the depen-
dence on EZH2 function.
Our data suggest that DZNeP inhibits SNAIL and
TGFBR2, two master regulators of EMT in prostate can-
cer cells[34,35]. This is consistent with previous reports,
showing that EZH2 mediates EMT through TGF-b path-
way activation[14]. DZNeP seemed not to up-regulate
some known EZH2 targets, like E-cadherin (CDH1).
However, although CDH1 is silenced in some cancer cell
lines by PRC2[15], it is still expressed by parental DU145
cells[36]. In these cell line, CDH1 is silenced only during
migration and invasion[36]. Our experiments evaluated
the effects of DZNeP on basal DU145 expression,
because derivation of mRNA from invading cells is extre-
mely difficult. Thus, it is not surprising to find that
CDH1 is not up-regulated in our experimental condi-
tions. It is likely that DZNeP hinders CDH1 silencing
during DU145 cell invasion. SNAIL down-regulation may
be a mechanism to maintain CDH1 expression, thereby
inhibiting cell invasion. Indeed, PRC2 and SNAIL co-
operate to inhibit CDH1 expression during EMT[37].
Our findings that DZNeP almost completely abrogated
PS self-renewal, reduced CSC marker expression and
impaired invasion through a possible EMT in DU145 cells
is in line with our hypothesis, and show the potential of
this drug for anti-metastatic and CSC-specific treatment.
This is particularly interesting, since CSC are the seeds of
metastatic spreading [5], and since PC metastasis are the
main cause of cancer-related death [38].
In vivo injection of DZNeP pre-treated cells produced dif-
ferent results in LNCaP and DU145 cells (Figures 4C,D). In
the less tumorigenic cell line (LNCaP), 10 μMD Z N e Pw a s
able to significantly reduce tumor formation in NOD/SCID
mice. 1 μM DZNeP had no effect on tumorigenicity. These
results show that in vivo anti-CSC activity may require
higher drug doses, that are however achievable and safe in
animal models [18,39]. Similar results were obtained for the
anti-CSC activity of temozolomide in glioblastoma [40]. In
such a study, 500 μM temozolomide almost completely
abrogated glioblastoma CSC clonogenicity in vitro. How-
ever, the same drug concentration did not reduce the
percentage of Ki67-positive lesions formed after injection
into immunocompromised mice. Interestingly, this result
was obtained with a highly chemoresistant cell line (R28).
Future clinical trials should demonstrate that a 10 μM
DZNeP concentration is also clinically achievable and non-
toxic in humans. In addition, it is worthy to note that we
pre-treated cells with DZNeP and then injected alive cells.
Thus, our results specifically investigate the anti-tumori-
genic role of DZNeP, which is not dependent on its apopto-
tic activity on cancer cells [19]. In DU145 cells, DZNeP pre-
treatment did not affect tumor formation, but significantly
inhibited tumor growth. DZNeP-treated cells formed signif-
icantly smaller tumors after as many as 30 (1 μM) and 45
(10 μM) days post-injection. Since DU145 cells are more
stem-like and more dependent on PRC2 function, we think
that these cells can escape from DZNeP antitumorigenic
activity. Nonetheless, we found a long-lasting effect on
tumor growth. Our results may support the idea that
DZNeP is more active to prevent PC metastasis than to
treat local advanced PC.
In conclusion, we showed that DZNeP is able to
impair CSC self-renewal and in vivo tumor development
at doses that are safe in mouse models. This results can
pave the way to the investigation of DZNeP anticancer
activity in PC patients.
Additional material
Additional File 1: H3K27 trimethylation in LNCaP cells.: Western blot
data comparing untreated cells, and cells treated with DZNeP (5 μM, 3d).
Additional File 2: Annexin-PI staining of LNCaP (A) and DU145 (B)
cells treated with 5-AZA and TSA. Cells were treated at concentration
shown to be non-toxic for normal cells, as described in “Materials and
Methods”. Experiment were repeated twice. Here is shown one
representative experiment.
Additional File 3: PS number (A, C) and PS diameter (B, D) after
treatment with TSA and 5-AZA. Cells were treated at concentration
shown to be non-toxic for normal cells, as described in “Materials and
Methods”. Experiment were repeated twice. Here is shown one
representative experiment.
Additional File 4: effects of DZNeP on CD44
+/24
+ cells. LNCaP cells
were sorted as described under “"Flow cytometric analysis and
separation”. Cells were treated with 1 μM DZNeP (5 days) and cell
viability was assessed trough “Cell Titer Glo” assay (Promega).
Additional File 5: Gene expression changes in EMT-related genes
induced by DZNeP. DU145 cells were treated with DZNeP (10 μM, 3d).
Fold change refers to relative mRNA levels, measured as described in
“Materials and Methods”.
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